• If you are wondering whether Ocular Therapeutix at around US$8.91 is priced attractively or already reflecting a lot of optimism, starting with a clear look at value can help you frame that question.
• The stock has seen a mix of moves, with a 5.8% gain over the last 7 days, a 3.2% return over the past month, a 24.3% gain over 1 year, set against a 24.6% decline year to date and a 41.7% decline over 5 years.
• Over the past year, headlines have focused on Ocular Therapeutix as a specialist in eye related therapies and its position within the broader pharmaceuticals and biotech space. This context has helped shape how investors see both its potential and its risks, which is reflected in the share price path you see today.
• On Simply Wall St's valuation checks, Ocular Therapeutix currently has a valuation score of 2 out of 6. The sections that follow will walk through the standard valuation approaches behind that score, and then finish with a more holistic way to think about what the stock might be worth.

Ocular Therapeutix scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Ocular Therapeutix Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today to estimate what the business might be worth right now. Here, the model uses a 2 Stage Free Cash Flow to Equity approach.

Ocular Therapeutix currently has last twelve month free cash flow of $210.67 million loss. Analyst projections and Simply Wall St extrapolations point to free cash flow moving to $399 million by 2030. The projected path runs from $257 million loss in 2026, through smaller losses, and then into positive territory from 2028 onward.

Rolling these cash flow projections together and discounting them, the model arrives at an estimated intrinsic value of $93.63 per share. Compared with the recent share price of about $8.91, this implies the stock is 90.5% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ocular Therapeutix is undervalued by 90.5%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.

Approach 2: Ocular Therapeutix Price vs Sales

For companies where current earnings are less informative, price based on revenue can be a useful guide. This is why the P/S ratio is the preferred metric here. A higher P/S is often associated with stronger growth expectations or lower perceived risk, while a lower P/S can reflect more modest growth assumptions or higher uncertainty.

Ocular Therapeutix currently trades on a P/S ratio of 37.34x. This stands well above the Pharmaceuticals industry average P/S of 4.67x and the peer average of 1.32x. On the surface, that gap suggests the market is assigning a much richer sales multiple to Ocular Therapeutix than to many of its industry peers.

Simply Wall St’s Fair Ratio aims to refine that comparison. It is a proprietary estimate of what the company’s P/S might be, based on factors such as earnings growth, profit margins, risk profile, industry and market cap. Because it adjusts for those elements, it can be more tailored than a simple peer or industry comparison. For Ocular Therapeutix, the Fair Ratio stands at 0.19x, which is far below the current P/S of 37.34x. This indicates the shares look overvalued on this sales based view.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose Your Ocular Therapeutix Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple way for you to spell out the story you believe about Ocular Therapeutix, link that story to a set of revenue, earnings and margin forecasts, and arrive at your own Fair Value that can then be compared with the current share price.

On Simply Wall St, Narratives sit inside the Community page and are designed to be easy to use. You can pick or adapt a view that fits you, whether that is closer to the cautious Fair Value of US$18 or the more optimistic US$34. Both are based on different assumptions about Axpaxli, future trial outcomes, margins and growth.

Each Narrative connects three things in one place: the business story, a financial model that projects earnings and cash flows, and a resulting Fair Value. It then refreshes that Fair Value automatically when new information such as earnings, trial results or bid reports is added to the platform.

This means you can quickly see how your chosen Ocular Therapeutix Narrative lines up with today’s price and decide whether the gap between Price and Fair Value looks attractive, stretched or close enough that you would rather wait for the next piece of news.

Do you think there's more to the story for Ocular Therapeutix? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.